Clinical Trials Logo

Skin Squamous Cell Carcinoma clinical trials

View clinical trials related to Skin Squamous Cell Carcinoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03353077 Completed - Clinical trials for Skin Squamous Cell Carcinoma

Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT)

Start date: November 21, 2017
Phase: N/A
Study type: Interventional

A unique approach for Skin Squamous Cell Carcinoma (SCC) treatment employing intratumoral diffusing alpha radiation emitter device

NCT ID: NCT03108131 Completed - Clinical trials for Locally Advanced Malignant Neoplasm

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Start date: April 7, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well cobimetinib and atezolizumab work in treating participants with rare tumors that have spread to other places in the body (advanced) or that does not respond to treatment (refractory). Cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cobimetinib and atezolizumab may work better in treating participants with advanced or refractory rare tumors.

NCT ID: NCT01807546 Completed - Clinical trials for Head and Neck Squamous Cell Carcinoma

Oral Rigosertib for Squamous Cell Carcinoma

Start date: March 2013
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine if tumors in patients with papillomavirus (HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard therapy will decrease in size following treatment with the investigational drug, rigosertib sodium (ON 01910.Na). A secondary objective is to determine if treatment with rigosertib causes any side effects. Rigosertib is an investigational drug, which means that it has not been approved by the U.S. Food and Drug Administration (FDA) to treat any diseases. We are studying rigosertib as a new anticancer drug. Tests that we have done in the laboratory suggest that rigosertib works by blocking cell division in cancer cells and causing them to die.